Wedbush Issues Neutral Recommendation on STAAR Surgical Amid Bullish Analyst Consensus

Wedbush Securities launched coverage of STAAR Surgical (STAA) in early February 2026 with a neutral recommendation, even as the broader analyst community maintains an optimistic outlook on the medical device company. The divergence between Wedbush’s cautious stance and market expectations highlights the complexity in evaluating the company’s growth trajectory, particularly as institutional investors show mixed conviction on the near-term direction.

Strong Analyst Consensus Points to Significant Upside Potential

Wall Street’s price targets paint an optimistic picture for STAAR Surgical shareholders. As of mid-January 2026, the average one-year price target stands at $25.82 per share, suggesting potential gains of 43.12% from the then-current price of $18.04. The analyst forecasts span a wide range, from a conservative low of $16.16 to an ambitious high of $32.29, reflecting varying views on the company’s execution capabilities.

Beyond stock appreciation, analysts project robust business expansion. The company is expected to generate $584 million in annual revenue, representing a projected increase of 153.38% year-over-year. On the profitability front, the projected non-GAAP EPS reaches 3.77, underscoring the operational leverage analysts anticipate as the business scales.

Mixed Institutional Signals in Fund Positioning

The institutional landscape for STAA reveals a nuanced picture of investor conviction. A total of 367 funds and institutions report positions in STAAR Surgical, though this represents a slight decline of 17 owners (down 4.43%) from the previous quarter. This modest pullback suggests some caution among marginal holders, despite the broader bullish recommendation environment.

Average portfolio allocation to STAA across all institutional holders stood at 0.29%, up 76.34% quarter-over-quarter. Total institutional share ownership increased by 0.71% to 58.233 million shares over the three-month period. However, the put/call ratio of 1.57 signals that options traders are positioning for a bearish near-term move, creating tension between fundamental bullishness and technical positioning.

Major Shareholders Navigate Divergent Strategies

Large stakeholders in STAAR Surgical have taken distinctly different approaches to their positions. Broadwood Capital remains the dominant shareholder with 13.519 million shares, representing 27.18% of the company. The firm maintained its stake unchanged during the most recent quarter, suggesting confidence in current levels.

Meanwhile, some institutional players are reducing exposure. The iShares Core S&P Small-Cap ETF (IJR) trimmed its holdings from 3.043 million shares to 2.951 million shares, a 3.14% decrease. The fund correspondingly reduced its STAA allocation by 8.50% over the quarter. Similarly, the iShares Russell 2000 ETF (IWM) cut its position from 1.313 million to 1.244 million shares (a 5.52% decline), with an 8.94% reduction in portfolio weight.

In contrast, other investors are doubling down. Yunqi Capital increased its holdings by 3.55% to 2.5 million shares (5.03% ownership), expanding its portfolio allocation by 36.09% in the process. Most notably, Balyasny Asset Management initiated a new position of 1.814 million shares after owning none previously, signaling fresh institutional interest in the stock.

The Neutral Recommendation and What It Means

Wedbush’s neutral recommendation, despite the broad analyst enthusiasm, suggests the firm may see the current valuation as appropriately reflecting near-term prospects, even if longer-term fundamentals remain supportive. This cautious posture from a major investment bank provides a counterweight to the more optimistic consensus, reminding investors that even in bullish markets, prudent portfolio positioning may warrant a measured approach.

The divergence between the neutral recommendation and the 43% upside target reflects an important lesson for individual investors: strong growth expectations don’t automatically translate to immediate stock outperformance. The varying institutional responses—with some reducing stakes while others aggressively increase—underscore the complexity of timing entry points in fundamentally improving but already-appreciated securities.